Shuttle Pharmaceuticals Holdings, Inc.
News
Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
Globe Newswire GAITHERSBURG, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals, a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients...\n more…
Shuttle Pharma Provides Second Quarter 2024 Corporate Update
Globe Newswire GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ( Shuttle Pharma ), a discovery and development stage specialty pharmaceutical company...\n more…
Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Globe Newswire GAITHERSBURG, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ( Shuttle Pharma or the Company ), a discovery and development stage specialty...\n more…
Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)
Globe Newswire GAITHERSBURG, Md., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ( Shuttle Pharma or the Company ), a discovery and development stage specialty...\n more…
Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
Globe Newswire GAITHERSBURG, Md., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ( Shuttle Pharma ), a discovery and development stage specialty pharmaceutical company...\n more…
